Atlas of AIDS pp 237-255 | Cite as

AIDS-Associated Malignancies

  • Susan E. Krown
  • Josephine Paredes


Primary Central Nervous System Lymphoma Pegylated Liposomal Doxorubicin Liposomal Anthracyclines Invasive Anal Cancer Dose Chemotherapy Regimen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rabkin CS, Janz S, Lash A, et al.: Monoclonal origin of multicentric Kaposi’s sarcoma lesions. N Engl J Med 1997, 336:988–993.PubMedCrossRefGoogle Scholar
  2. 2.
    Moore PS, Chang Y: Kaposi’s sarcoma-associated herpesvirus-encoded oncogenes and oncogenesis. J Natl Cancer Inst Monogr 1998, 23:65–71.PubMedCrossRefGoogle Scholar
  3. 3.
    Krown SE: Kaposi’s sarcoma. In Principles and Practice of the Biological Therapy of Cancer, edn 3. Edited by Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2000:256–275.Google Scholar
  4. 4.
    Krown SE: Diagnosis and treatment of AIDS-associated Kaposi’s sarcoma. In AIDS-related Cancers and Their Treatment Edited by Feigal EG, Levine AM, Biggar RJ. New York: Marcel Dekker; 2000:59–95.Google Scholar
  5. 5.
    Gill PS, Wernz J, Scadden DT, et al.: Randomized phase II trial of liposomal daunorubicin (DaunoXome) versus doxorubicin, bleomycin, vincristine (ABV) in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1996, 14:2353–2364.PubMedGoogle Scholar
  6. 6.
    Stewart S, Jablonowski H, Goebel FD, et al.: Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncoi 1998:683–691.Google Scholar
  7. 7.
    Northfelt DW, Dezube BJ, Thommes JA, et al.: Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol 1998, 16:2445–2451.PubMedGoogle Scholar
  8. 8.
    Welles L, Saville MW, Lietzau J, et al.: Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi’s sarcoma. J Clin Oncol 1998, 16:1112–1121.PubMedGoogle Scholar
  9. 9.
    Gill PS, Tulpule A, Espina BM, et al.: Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi’s sarcoma. J Clin Oncol 1999, 17:1876–1883.PubMedGoogle Scholar
  10. 10.
    Ho DD, Hartshorn KL, Rota TR, et al.: Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro, Lancet 1985, 1:602–604.CrossRefGoogle Scholar
  11. 11.
    Tilg H, Mier JW, Vogel W, et al.: Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol 1993, 150:4687–4692.PubMedGoogle Scholar
  12. 12.
    Ezekowitz RAB, Mulliken JB, Folkman J: Interferon alfa-2a for life-threatening hemangiomas of infancy. N Engl J Med 1992, 326:1456–1463.PubMedCrossRefGoogle Scholar
  13. 13.
    Krown SE, Myskowski PL, Paredes J: Kaposi’s sarcoma: Management of Kaposi’s sarcoma in HIV-infected patients. Med Clin North Am 1992, 76:235–252.PubMedGoogle Scholar
  14. 14.
    Pitha P: Multiple effects of interferon on HIV-1 replication. J Interferon Res 1991, 11:313–318.PubMedCrossRefGoogle Scholar
  15. 15.
    Hartshorn KL, Vogt MW, Chou TC, et al.: Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant inter-feron-alpha A. Antimicrob Agents Chemother 1987, 31:168–172.PubMedCrossRefGoogle Scholar
  16. 16.
    Johnson VA, Merrill DP, Videler JA, et al.: Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 syner-gistically in vitro. J Infect Dis 1991, 164:646–655.CrossRefGoogle Scholar
  17. 17.
    Vogt MW, Durno AG, Chou TC, et al.: Synergistic interaction of 2’, 3’-dideoxycytidine (ddCyd) and recombinant interferon alpha A (rIFN-alpha A) on HIV-1 replication. J Infect Dis 1988, 158:378–385.PubMedCrossRefGoogle Scholar
  18. 18.
    Scadden DT, Bering HA, Levine JD, et al.: Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi’s sarcoma. J Clin Oncol 1991, 9:802–808.PubMedGoogle Scholar
  19. 19.
    Krown SE, Paredes J, Bundow D, et al.: Interferon-alpha, zidovudine, and granulocyte-macrophage colony-stimulating factor: A phase I AIDS Clinical Trials Group study in patients with Kaposi’s sarcoma associated with AIDS. J Clin Oncol 1992, 10:1344–1351.PubMedGoogle Scholar
  20. 20.
    Krown SE, Li P, VonRoenn J, Testa M: Multicenter, randomized, open-label, phase II trial of two doses of interferon (IFN)-α2b with didanosine (ddI) in HIV-related Kaposi’s sarcoma: ACTG 206 [abstract]. J Acquir Immune Defic Syndr Human Retrovir 2000, 23:A22.Google Scholar
  21. 21.
    Jones JL, Hanson DL, Chu SY, et al.: AIDS-associated Kaposi’s sarcoma [letter]. Science 1995, 267:1078–1079.PubMedCrossRefGoogle Scholar
  22. 22.
    Mocroft A, Youle M, Gazzard B, et al.: Anti-herpesvirus treatment and risk of Kaposi’s sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals collaborative group. AIDS 1996, 10:1101–1105.PubMedCrossRefGoogle Scholar
  23. 23.
    Knowles DM, Inghirami G, Ubriaco A, et al.: Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus. Blood 1989, 73:792–799.PubMedGoogle Scholar
  24. 24.
    Ballerini P, Gaidano G, Gong JZ, et al.: Multiple genetic lesions in AIDS-related non-Hodgkin lymphoma. Blood 1993, 81:166–176.PubMedGoogle Scholar
  25. 25.
    Kaplan LD, Straus DJ, Testa MA, et al.: Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkins’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997, 336(23)1641–1648.PubMedCrossRefGoogle Scholar
  26. 26.
    Straus DJ, Huang J, Testa MAet al.: Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: analysis of AIDS Clinical Trials Group protocol 142-low dose versus standard dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998, 16:3601–3606.PubMedGoogle Scholar
  27. 27.
    Scadden DT. Non-Hodgkin’s lymphoma: future targets for prevention and therapy. In AIDS-related Cancers and Their Treatment. Edited by Feigal EG, Levine AM, Biggar RJ. New York: Marcel Dekker; 2000:195–207.Google Scholar
  28. 28.
    Baumgartner JE, Rachlin JR, Beckstead JH, et al.: Primary central nervous system lymphoma: Natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome. J Neurosurg 1990, 73:206–211.PubMedCrossRefGoogle Scholar
  29. 29.
    Nisce LZ, Metroka C: Radiation therapy in patients with AIDS-related central nervous system lymphoma. JAMA 1992, 267:1921–1922.PubMedCrossRefGoogle Scholar
  30. 30.
    Forsyth PA, Yahalom J, DeAngelis LM, et al.: Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS. Neurology 1994, 44:1473–1479.PubMedCrossRefGoogle Scholar
  31. 31.
    Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990, 248:76–79.PubMedCrossRefGoogle Scholar
  32. 32.
    Dyson N, Howley PM, Munger K, et al.: The human papilloma virus-16 E7 oncoprotein is able to bind the retinoblastoma gene product. Science 1989,243:934–937.PubMedCrossRefGoogle Scholar
  33. 33.
    Maiman M, Fruchter RG, Guy L, et al.: Human immunodeficiency virus infection and invasive cervical carcinoma. Cancer 1993, 71:402–406.PubMedCrossRefGoogle Scholar
  34. 34.
    Lorenz HP, Wilson W, Leigh B, et al.: Squamous cell carcinoma of the anus and HIV infection. Dis Colon Rectum 1991, 34:336–338.PubMedCrossRefGoogle Scholar
  35. 35.
    Rabkin CS, Biggar RJ, Horn J: Cancer trends associated with increasing AIDS. In the Proceedings of the VI International Conference on AIDS, San Francisco, 1990, 1:295.Google Scholar
  36. 36.
    Svensson C, Kaigas M, Lindbrink E, et al.: Carcinoma of the anal canal in a patient with AIDS. Acta Oncol 1991, 30:8986–8991.CrossRefGoogle Scholar
  37. 37.
    Maiman M, Tarricons N, Viera J, et al.: Colposcopic evaluation of human immunodeficiency virus seropositive women. Obstet Gynecol 1991, 78:84–88.PubMedGoogle Scholar

Selected Bibliography

  1. Feigal EG, Levine AM, Biggar RJ: AIDS-related Cancers and Their Treatment. New York: Marcel Dekker; 2000.Google Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Susan E. Krown
  • Josephine Paredes

There are no affiliations available

Personalised recommendations